Recombinant Matrix Metalloproteinase-9 Induces Ventricular Remodeling By Up-Regulating Angiotensin II
| العنوان: | Recombinant Matrix Metalloproteinase-9 Induces Ventricular Remodeling By Up-Regulating Angiotensin II |
|---|---|
| المؤلفون: | Xin-chao You, Wan-xing Zhou, Wei Zhang, Rui-ying Li, Yu-lan Song, Li-zhi Chen, Lu-yuan Luo, Si-qi Gu |
| المصدر: | American Journal of Hypertension. 33:205-206 |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cardiac function curve, Necrosis, biology, business.industry, Angiotensin-converting enzyme, medicine.disease, Angiotensin II, Cell biology, law.invention, Cytolysis, Cytoplasm, law, Internal Medicine, biology.protein, medicine, Recombinant DNA, medicine.symptom, business, Ventricular remodeling |
| الوصف: | Objective To study the effect of matrix metalloproteinase-9 (MMP-9) on ventricular remodeling and involvement of angiotensin II (Ang II). Methods Thirty-six adult male Wistar rats were randomly divided into control (n = 12), MMP-9 (n = 12), and MMP-9 + olmesartan (n = 12) groups. Recombinant MMP-9 (2.1 ng/g) was injected intraperitoneally twice a week. Olmesartan (3 mg/kg) was given by oral gavage once daily. Animals were treated for 4 or 8 weeks. Cardiac function was assessed by echocardiography followed by histological analysis. The messenger RNA (mRNA) and protein levels of MMP-9 in myocardial tissues were analyzed by reverse transcription polymerase chain reaction and Western blotting, respectively. Serum levels of Ang I, II, angiotensin converting enzyme (ACE) and MMP-9 were determined by enzyme-linked immunosorbent assay (ELISA). Results MMP9 administration for 4 or 8 weeks increased mRNA and protein levels of MMP-9 in myocardial tissues, serum levels of MMP-9, Ang I, II and ACE, and left ventricular mass index (LVMI) but decreased collagen volume fraction (CVF) compared with the control group (all P < 0.05). Cardiomyocyte cell size was significantly enlarged and disorganized with cytoplasmic lysis and necrosis in the MMP-9 group. After olmesartan treatment, myocardial MMP-9 mRNA and protein levels, serum levels of MMP-9 and Ang II, and LVMI were lower, and CVF was higher with significant improvement in myocardial morphology and cardiac function (all P Conclusion Recombinant MMP-9 treatment induces ventricular remodeling and cardiac dysfunction by up-regulating Ang II. |
| تدمد: | 1941-7225 0895-7061 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::88c92eb6d6c6a763e9465457fd8b023f https://doi.org/10.1093/ajh/hpz189 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........88c92eb6d6c6a763e9465457fd8b023f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19417225 08957061 |
|---|